Bispecific T-Cell Engagers Market Set to Reach $4.18 Billion by 2030, Driven by Technological Advancements and Growing Healthcare Investments.

Kahn Swick & Foti, LLC is investigating CarMax, Inc. (KMX) regarding its second quarter Fiscal Year 2026 financial results, which disclosed a decrease in retail unit sales, net earnings, and the unexpected departure of its CEO. The investigation is focused on whether CarMax's officers and directors breached their fiduciary duties to shareholders or violated state or federal laws. If you have information that could assist the investigation or were a long-term holder of CarMax shares, you may contact the firm for more information.